TrueBinding Inc. is an early stage biotherapeutics development company focused on creating new and exciting molecules for applications in immuno oncology and other disease areas with great unmet medical need.


Based on the application of the TruebindingTM platform, TrueBinding has to date discovered 6 novel ligands, previously uncharacterized, to receptors of known checkpoint inhibitor pathways.



As compared to traditional approaches such as membrane protein library screening,

Our  proprietary technology is proven to be powerful to discover new targets  and their binding partners. And we can verify them by vary assays



Currently, the lead program has multiple components with respect to data; the proof and characterization of a new ligand for Tim-3 along with the antibody development and demonstration of activity in in vivo tumor models.


Earlier programs are at various stages of development, focusing on therapeutic antibody generation to block our newly discovered checkpoint inhibitor interactions



Dr. Dongxu Sun
Co-founder &  CEO

PhD, University of Minnesota.  Postdoc, Cornell Medical College. Project Scientist, Cleveland Clinic.

Worked at ImmuNext, 

Successfully identified new protein binding partners in novel signaling pathways of IFNg. 


MD. Peter Traber

Ex. President and CEO of Galetin Therapeutics

President and CEO of Baylor College of Medicine

SVP and CMO at GSK.

Dean of UPenn Medical Schcool

Dr. Fan Chen
SVP of Biologics and CMC

20+ years experience in bioprocess development

. VP of Process Development at LakePharma,

Senior  leader of process development at Dendreon/MedImmune/




For any inquiries, questions or commendations, please fill out the following form


Senior Scientist/Scientist Immune Oncology

We are seeking a highly motivated individual with experience in immunology or related fields to join us at this exciting moment. The primary focus of the job is identification and characterization of novel targets and contribution in the development of new drugs for cancer immunotherapy and other disease indications.

Education and Experience: 

  • Ph.D, or Master with 5-year working experience in Immunology or related fields. 

  • Expertise in ex vivo assays assessing various immune populations, including T cells, macrophages, and DCs

  • Experience in in vivo mouse tumor models is a plus

  • Expertise in multi-color (>5 color) flow cytometer

  • A willingness to learn and adopt new experimental skills as needed.

If interested, please contact Dr. Sun at

Dr. Mark Selby

Inventor of Ipilimumab and Nivolumab

Senior director at BMS

Associated director at Medarex,

MD.  Mitchel Berger

Chair of neurological surgery department at UCSF

Director of the Brain Tumor Research Center

President, American Association of Neurological Surgeons

President, American Academy of Neurological Surgery

Professor Debbie Thurmond

Key opinion leader in the field of Diabetes and Metabolism. 

Founding Chair of the Department of Molecular & Cellular Endocrinology at the City of Hope Beckman Research Institute

Deputy Director of the Diabetes & Metabolism Research Institute

© 2018 by TrueBinding Inc.

1140A O'Brien Drive.

Menlo Park, CA. 94025

Tel: 650 785 0225